The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
- PMID: 30006934
- DOI: 10.1002/cpt.1149
The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Abstract
Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.
© 2018 American Society for Clinical Pharmacology and Therapeutics.
Comment in
-
Risk of Bias and Quality of Evidence for Treatment of ADHD With Stimulant Medication.Clin Pharmacol Ther. 2018 Oct;104(4):638-643. doi: 10.1002/cpt.1186. Epub 2018 Sep 4. Clin Pharmacol Ther. 2018. PMID: 30066372
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
